Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

A Study of [14C]-LY3023703 in Healthy Participants

30 de julio de 2018 actualizado por: Eli Lilly and Company

Disposition of [14C]-LY3023703 Following Oral Administration in Healthy Subjects

This type of study is called a radiolabeled study. For this study, LY3023703 (study drug) has been specially prepared to contain radiolabeled carbon [14C]. [14C] is a naturally occurring radioactive form of the element carbon. This study will help understand how the drug appears in the blood, urine, and stool after it is administered to healthy men. Information about any side effects that may occur will also be collected. This study will last up to 15 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

18

Fase

  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Wisconsin
      • Madison, Wisconsin, Estados Unidos, 53704
        • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 65 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Masculino

Descripción

Inclusion Criteria:

  • Participants will either be sterile or, if sexually active, agree to use approved methods of contraception from the day before dosing until 3 months after the follow-up assessment
  • Participants will refrain from sperm donation from the day before dosing until 3 months after the follow-up assessment
  • Have a body mass index (BMI) of 18.5 to 32.0 kilogram per meter square (kg/m^2)
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • Have given written informed consent approved by Lilly and the IRB governing the site

Exclusion Criteria:

  • Are currently enrolled in, have participated, within the last 30 days, in a clinical trial involving an investigational product, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Are participants who have previously completed or withdrawn from this study or any other study investigating LY3023703, and have previously received the investigational product
  • Have known allergies to LY3023703, related compounds or any components of the formulation, or history of significant atopy
  • Have recent or ongoing gastrointestinal (GI) symptoms or illnesses, have a history of GI bleeding or perforation, related to previous nonsteroidal anti-inflammatory drug (NSAID) or cyclooxygenase (COX)2 inhibitor therapy or have active or history of recurrent peptic ulcer/hemorrhage (2 or more distinct episodes of proven ulceration or bleeding)
  • Have a history of intolerance to NSAIDs or aspirin
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of alanine aminotransferase or aspartate aminotransferase levels above the normal ranges, confirmed on repeat, or a history of elevated and abnormal liver tests
  • Have intended use of over-the-counter medications or prescription medication within 14 days prior to dosing. Also within 30 days prior to dosing, any drugs and dietary items that are known inducers or inhibitors of cytochrome P450 (CYP) 3A or CYP2J2 or other drugs that may affect the disposition of LY3023703 or increase risk for complications from the study
  • Have consumed herbal supplements within 14 days prior to admission or grapefruit juice, grapefruits, grapefruit-containing products, Seville orange juice, Seville oranges, star fruit, or star fruit juice within 7 days prior to dosing or intend to consume during the study
  • Have donated blood of more than 500 milliliter (mL) within the last month
  • Have participated in a [14C]-study within the last 6 months prior to admission for this study
  • Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
  • A positive alcohol breathalyzer test
  • A positive cotinine test
  • Are unwilling to refrain from consuming xanthine-containing food and drink from 48 hours prior to admission until discharge from the Clinical Research Unit (CRU)
  • Have a defecation pattern less than once per 2 days or acute constipation within 3 weeks of the day before dosing
  • In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Ciencia básica
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: [^14C]-LY3023703
Single oral dose of 15 mg LY3023703, containing approximately 100 µCi [^14C] labeled drug, administered as an oral solution.
Administered orally

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Fecal Excretion of LY3023703 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Periodo de tiempo: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Urinary Excretion of LY3023703 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Periodo de tiempo: Predose up to 168 hours post dose
Predose up to 168 hours post dose

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
Pharmacokinetics of LY3023703 and Radioactivity Maximum Observed Concentration (Cmax)
Periodo de tiempo: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Pharmacokinetics of LY3023703 and Radioactivity Time of Maximum Observed Concentration (Tmax)
Periodo de tiempo: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Pharmacokinetics of LY3023703 and Radioactivity Area Under The Concentration-Time Curve From Time Zero to the Last Timepoint With a Measurable Concentration [AUC (0 to Tlast)]
Periodo de tiempo: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Relative Abundance of LY3023703 and the Metabolites of LY3023703 in Urine and Feces
Periodo de tiempo: Predose up to 168 hours post dose
Predose up to 168 hours post dose
Relative Abundance of LY3023703 and the Metabolites of LY3023703 in Plasma
Periodo de tiempo: One hour post-dose up to 72 hours post dose
One hour post-dose up to 72 hours post dose

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de octubre de 2013

Finalización primaria (Actual)

1 de octubre de 2013

Finalización del estudio (Actual)

1 de octubre de 2013

Fechas de registro del estudio

Enviado por primera vez

16 de octubre de 2013

Primero enviado que cumplió con los criterios de control de calidad

16 de octubre de 2013

Publicado por primera vez (Estimar)

18 de octubre de 2013

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de agosto de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

30 de julio de 2018

Última verificación

1 de julio de 2018

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 15097
  • I6H-MC-MCBD (Otro identificador: Eli Lilly and Company)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir